Acta Endoscopica

, Volume 35, Issue 2, pp 157–169

Tumeurs intestinales, quelle stratégie proposer?

  • A. Caunedo
  • J. M. Herrerías
Article
  • 34 Downloads

Intestinal tumors: can a management strategy be proposed?

Résumé

Les tumeurs primitives de l’intestin grêle représentent seulement 50 % de toutes les tumeurs du tractus gastro-intestinal. Les manifestations cliniques de ces tumeurs ne sont pas spécifiques et leurs symptômes apparaissent tardivement. La rareté, la non spécificité des symptômes et leur inaccessibilité rend ces tumeurs de l’intestin grêle susceptibles de passer inaperçues, avec un diagnostic très souvent erroné et tardif, et d’être responsables d’un taux de mortalité élevé.

Le développement de la capsule endoscopique pour l’étude de l’intestin grêle et l’utilisation de l’imatinib dans les tumeurs stromales gastro-intestinales (TSGI) ont représenté d’importantes innovations dans le diagnostic et le traitement de ces patients. Cette étude a pour objet de discuter le rôle de ces deux nouveautés dans le traitement des tumeurs de l’intestin grêle et de proposer un algorithme pour leur diagnostic et traitement.

Summary

Primary small-bowel tumors are representing only 5 % of all primary tumors of the gastrointestinal tract. Clinical manifestations of these tumors are nonspecific and the neoplasmarelated symptoms occur lately. The rarity, non specific symptoms and inaccessibility make small bowel tumors liable to be overlooked, with frequent delayed or erroneous diagnosis, and are responsible for high mortality rates.

The development of capsule endoscopy for small bowel examination, as well as the use of imatinib in gastrointestinal stromal tumors (GIST), supposed outstanding innovations in diagnosis and therapy of these patients. The role of these two innovations in the management of small bowel tumors is discussed in this review and a diagnostic and therapeutic algorithm is proposed.

Mots-clés

algorithme capsule endoscopie imatinib tumeur de l’intestin grêle 

Key-words

algorithm capsule endoscopy imatinib small bowel tumors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Jemal A, Murray T, Samuels A, et al. Cancer Statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.PubMedGoogle Scholar
  2. 2.
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54 (1): 8–29.PubMedCrossRefGoogle Scholar
  3. 3.
    DiSario JA, Burt RW, Vargas H, et al. Small bowel cancer: epidemiological and clinical characteristics from a populationbased registry. Am J Gastroenterol 1994; 89: 699–701.PubMedGoogle Scholar
  4. 4.
    Neugut AI, Arber N. Epidemiology, molecular epidemiology, and molecular biology of small bowel and appendiceal adenocarcinomas. In: Abbruzzese J, ed. Principles and Practice of Gastrointestinal Oncology. Baltimore, Md: Lippincott Williams & Wilkins; 2001.Google Scholar
  5. 5.
    Jones DV Jr, Skibber J and Levin B. Adenocarcinoma and other small intestinal neoplasms, including benign tumors. In: Feldman M, Scharschmidt BF and Sleisenger MH. Gastrointestinal and liver disease: Pathophysiology, Diagnosis and Management. Philadelphia, WB Saunders Company; 1998.Google Scholar
  6. 6.
    Lance P. Tumors and other neoplastic diseases of the small intestine. In: Yamada T, Alpers DH, Laine L, Owyang C and Powell DW eds. Text book of Gastroenterology. Philadelphia, Lippincott Williams & Wilkins; 1999.Google Scholar
  7. 7.
    Frost DB, Mercado PD, Tyrell JS, et al. Small bowel cancer: a 30-year review. Ann Surg Oncol 1994; 1: 290–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Cunningham JD, Aleali R, Aleali M, et al. Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival. Ann Surg 1997; 225: 300–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Ohja A, Zacherl J, Scheuba C et al. Primary small bowel malignancies: single-center results of three decades. J Clin Gastroenterol 2000; 30: 289–93.CrossRefGoogle Scholar
  10. 10.
    Bauer RL, Palmer ML, Bauer AM, et al. Adenocarcinoma of the small bowel intestine: 21-year review of diagnosis, treatment and prognosis. Annals of Surgical Oncology 1994; 1: 183–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Talamonti MS, Goetz LH, Rao S, et al. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 2002; 137: 564–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Yang Y-S, Huang Q-Y, Wang W-F, et al. Primary jejunoileal neoplasmas: a review of 60 cases. World J Gastroenterol 2003; 9: 862–4.PubMedGoogle Scholar
  13. 13.
    North JH, Pack MS. Malignant tumors of the small intestine: a review of 144 cases. Am Surg 2000; 66: 46–51.PubMedGoogle Scholar
  14. 14.
    García Marcilla JA, Sánchez Bueno F., Aguilar J, et al. Primary small bowel malignant tumors. Eur J Surg Oncol 1994; 20: 630–4.Google Scholar
  15. 15.
    Blanchard DK, Budde JM, Hatch GF 3rd. Tumors of the small intestine. World J Surg 2000; 24: 421–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Nolan DJ and Traill ZC. The current role of the barium examination of the small bowel. Clin Radiol 1997; 52: 809–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Bloomfeld RS, Smith TP, Schneider AM, Rockey DC. Provocative angiography in patients with gastrointestinal hemorrhage of obscure origin. Am J Gastroenterol 2000; 95: 2807–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Maccioni F, Rossi P, Gourtsoyiannis N, et al. Broglia L. US and CT findings of small bowel neoplasms. Eur Radiol 1997; 7: 1398–1409.PubMedCrossRefGoogle Scholar
  19. 19.
    Landi B, Tkoub M, Gaudric M et al. Diagnostic yield of pushenteroscopy in relation to indication. Gut 1998; 42: 421–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Lewis B, Kornbluth A, Waye J. Small bowel tumors: the yield of enteroscopy. Gut 1991; 32: 763–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Douard R, Wind P, Panis Y, et al. Intraoperative enteroscopy for diagnosis and management of unexplained gastrointestinal bleeding. Am J Surg 2000;180:181–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Iddan G, Meron G, Glukhovsky A and Swain P. Wireless capsule endoscopy. Nature 2000; 405: 417.PubMedCrossRefGoogle Scholar
  23. 23.
    Gong F, Swain P and Mills T. Wireless endoscopy. Gastrointest Endosc 2000; 51: 725–29.PubMedCrossRefGoogle Scholar
  24. 24.
    Ell C, Remke S, May A, Helou L, Henrich R, Mayer G. The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding. Endoscopy 2002; 34: 685–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Lewis BS and Swain P. Capsule endoscopy in the evaluation of patients with suspected small intestinal bleeding: results of a pilot study. Gastrointest Endosc 2002; 56: 349–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Pennazio M, Santucci R, Rondonotti E, et al. Clinical outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: report of 100 consecutive cases. Gastroenterology 2004; 126: 643–53.PubMedCrossRefGoogle Scholar
  27. 27.
    Herrerías JM, Caunedo A, Rodríguez-Téllez M, Pellicer FJ, Herrerías JM Jr. Capsule endoscopy in patients with suspected Crohn’s disease in negative endoscopy. Endoscopy 2003; 35: 564–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Fireman Z, Majan E, Broide E, et al. Diagnosing small bowel Crohn’s disease with wireless capsule endoscopy. Gut 2003; 52: 390–2.PubMedCrossRefGoogle Scholar
  29. 29.
    Romero J, Gómez BJ, Caunedo A, et al. NSAIDs erosive enteropathy assessed by capsule endoscopy: a prospective controlled trial. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 91.Google Scholar
  30. 30.
    Graham DY, Qureshi WA, Willingham F et al. A controlled study of NSAID-induced small bowel injury using video capsule endoscopy. Gastroenterology 2003; 124: A19.CrossRefGoogle Scholar
  31. 31.
    Pennazio M, Arrigoni A, Sprujevnik T, Bertone A, Cavallero M, Spandre M, et al. Autoimmune polyglandular syndrome type II associated with gastrointestinal stromal tumor: diagnosis by capsule endoscopy. Endoscopy 2004; 36: 248–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Alcázar J, Romero J, Rodríguez-Téllez M, Caunedo A, Pellicer F and Herrerías JM. A 65-years-old woman with intense ferropenic anemia. Proceedings of 1st Iberian meeting on capsule endoscopy. Seville, 2003, 118.Google Scholar
  33. 33.
    De Franchis R, Rondotti E, Abbiati C, et al. Small Bowel malignancy. Gastrointest Endosc Clin N Am 2004;14: 139–48.PubMedCrossRefGoogle Scholar
  34. 34.
    Cobrin GM, Pittman RH and Lewis BS. Diagnosing small bowel tumors with capsule endoscopy. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 41.Google Scholar
  35. 35.
    Keuchel M, Thaler C, Caselitz J, and Hagenmuller F. Diagnosis of small bowel tumors with video capsule endoscopyreport of 16 cases. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 43.Google Scholar
  36. 36.
    Mascarenhas-Saraiva M, Da Silva LM. Small bowel tumors diagnosed by wireless capsule endoscopy: report of five cases. Endoscopy 2003; 35: 865–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Gay G, Laurent V, Fassler I, Delvaux M. Interest of the endoscopic videocapsule to detect intestinal tumors. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 135.Google Scholar
  38. 38.
    Menchén L, González-Asanza C, Díaz-Redondo A, De la Cruz G, Beceiro I, Alberdi J, et al. Small bowel neoplasms in patients with obscure gastrointestinal bleeding; diagnosis with capsule endoscopy. Endoscopy 2003; 35 [Suppl II]: A183.Google Scholar
  39. 39.
    Toth E, Fork FT, Syk I, Ljungberg O, Stewenius J, Lindström M, et al. Diagnosis of small bowel tumors by capsule endoscopy in patients with obscure gastrointestinal bleeding. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 195.Google Scholar
  40. 40.
    Romero-Vázquez J, Caunedo A, Alcázar J, et al. Tumores de intestino delgado en una serie de 400 capsuloendoscopias. Proceedings of the “ XXXV Reunión de la Sociedad Andaluza de Patología Digestiva”. Seville, 2004.Google Scholar
  41. 41.
    Madisch A, Schimming W, Kinzel F, Schneider R, Aust D, Ockert DM, et al. Locally advanced small-bowel adenocarcinoma missed primarily by capsule endoscopy but diagnosed by push enteroscopy. Endoscopy 2003; 35: 861–5.PubMedCrossRefGoogle Scholar
  42. 42.
    De Franchis R, Devani M, Randotti E, et al. Study of neuroendocrine neoplasms of the small Borrel with capsule endoscopy: report of two cases. Proceedings of the 3rd Conference on Capsule Endoscopy. Miami, 2004, 97.Google Scholar
  43. 43.
    Caunedo A, Jimenez-Sáenz M, Romero R, Pellicer FJ, Herrerías JM. The role of capsule endoscopy in the assessment of gastrointestinal lymphomas. Proceedings of the 1st Conference on Capsule Endoscopy. Rome, 2002, 75.Google Scholar
  44. 44.
    Jimenez-Sáenz M, Caunedo A, Rodríguez-Téllez M, Romero R, Herrerías JM et al. Capsule endoscopy in the surveillance of patients with primary small bowel lymphoma (case report). Proceedings of the 1st Conference on Capsule Endoscopy. Rome, 2002, 137.Google Scholar
  45. 45.
    Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001; 2: 485–91.PubMedCrossRefGoogle Scholar
  46. 46.
    Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 41–7.PubMedGoogle Scholar
  47. 47.
    Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal tumors of the jejunum and ileum. Mod Pathol 1997; 10: 200–9.Google Scholar
  48. 48.
    Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–80.PubMedCrossRefGoogle Scholar
  49. 49.
    Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78: 1633–6.PubMedGoogle Scholar
  50. 50.
    Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. Histopathology 1999; 34: 416–24.PubMedCrossRefGoogle Scholar
  51. 51.
    Moskaluk CA, Tian Q, Marshall CR, et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999; 18: 1897–1902.PubMedCrossRefGoogle Scholar
  52. 52.
    Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154: 53–60.PubMedGoogle Scholar
  53. 53.
    Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297–4300.PubMedGoogle Scholar
  54. 54.
    Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484–95.PubMedCrossRefGoogle Scholar
  55. 55.
    Fletcher JA, Fletcher CD, Rubin BP, et al. KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized? Am J Pathol 2002; 161: 737–8.PubMedGoogle Scholar
  56. 56.
    Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–10.PubMedCrossRefGoogle Scholar
  57. 57.
    Andersson J, Sjogren H, Meis-Kindblom JM, et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160: 15–22.PubMedGoogle Scholar
  58. 58.
    Gunawan B, Bergmann F, Hoer J, et al. Biological and clinical significance of cytogenetic abnormalities in low-risk and highrisk gastrointestinal stromal tumors. Hum Pathol 2002; 33: 316–21.PubMedCrossRefGoogle Scholar
  59. 59.
    Demetri GD, Titton RL, Ryan DP, et al. Case 32–2004: A 68-year-old man with a large retroperitoneal mass. N Engl J Med 2004; 351: 1779–87.PubMedCrossRefGoogle Scholar
  60. 60.
    Miettinen M, Lasota J. Gastrointestinal stromal tumors — definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1–12.PubMedCrossRefGoogle Scholar
  61. 61.
    Pidhorecky I, Cheney RT, Kaybill WG, et al. Gastrointestinal Stromal Tumors: Current Diagnosis, Biologic Behavior, and Management. Annals of Surgical Oncology, 2001; 7: 705–12.CrossRefGoogle Scholar
  62. 62.
    Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001; 2: 485–91.PubMedCrossRefGoogle Scholar
  63. 63.
    Suster S. Gastrointestinal stromal tumors. Semin Diagn Pathol 1996 Nov; 13 [4]: 297–313.PubMedGoogle Scholar
  64. 64.
    Casper ES. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2000; 1: 267–73.PubMedCrossRefGoogle Scholar
  65. 65.
    DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg 2001; 231: 51–8.CrossRefGoogle Scholar
  66. 66.
    Miettinen M, El-Rifai W, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002; 33: 478–83.PubMedCrossRefGoogle Scholar
  67. 67.
    Langer C, Gunawan B, Schuler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90: 332–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: consensus approach. Hum Pathol 2002; 3: 459–65.CrossRefGoogle Scholar
  69. 69.
    Connolly EM, Gaffney E and Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003; 90: 1178–86.PubMedCrossRefGoogle Scholar
  70. 70.
    Buchdunger, E, Cioffi, CL, Law, N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–45.PubMedGoogle Scholar
  71. 71.
    Savage DG, Antman KH. Imatinib mesylate — a new oral targeted therapy. N Engl J Med 2002; 346: 683–93.PubMedCrossRefGoogle Scholar
  72. 72.
    Heinrich MC, Griffith DJ, Druker B et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96: 925–32.PubMedGoogle Scholar
  73. 73.
    Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–10.PubMedCrossRefGoogle Scholar
  74. 74.
    Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63: 513–27.PubMedCrossRefGoogle Scholar
  75. 75.
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hématologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–52.PubMedCrossRefGoogle Scholar
  76. 76.
    Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hématologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–37.PubMedCrossRefGoogle Scholar
  77. 77.
    Sawyers CL, Hochhaus A, Feldman et al. Imatinib induces hematologie and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood 2002; 99: 3530–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Tuveson, D. A., Willis, N. A., Jacks, T., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 5054–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Mace J, Sybil Biermann J., Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95: 2373–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052–6.PubMedCrossRefGoogle Scholar
  81. 81.
    van Oosterom A, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421–3.PubMedCrossRefGoogle Scholar
  82. 82.
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • A. Caunedo
    • 1
  • J. M. Herrerías
    • 1
  1. 1.Gastro enterology Unit, «Virgen Macarena» University HospitalSevilleSpain

Personalised recommendations